Remove Gene Remove Gene Therapy Remove Scientist
article thumbnail

Scientists home in on cause of Duchenne gene therapy side effect

Bio Pharma Dive

An unusual collaboration among gene therapy developers suggests certain mutations could be behind "peculiar" side effects experienced by several patients treated in clinical trials.

article thumbnail

FDA grants approval for CSL’s haemophilia B gene therapy

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has granted approval for CSL Behring’s adeno-associated virus vector-based gene therapy, Hemgenix (etranacogene dezaparvovec), to treat haemophilia B (congenital Factor IX deficiency) in adult patients. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Cell and gene therapies: why advanced medicines call for specialised logistics

Pharmaceutical Technology

But scientists have struggled to find effective treatments for many of these diseases since the dawn of modern medicine. Recent years have seen a steadily growing number of approvals for cell and gene therapies, which has spurred on the community to continue innovating in this space. A new frontier in cancer research.

article thumbnail

FDA staff skeptical of Sarepta’s Duchenne gene therapy, documents show

Bio Pharma Dive

Sarepta has not provided “unambiguous evidence” its treatment can help patients, agency scientists wrote in documents released ahead of a crucial Friday advisory committee meeting.

article thumbnail

Roche launches new Boston center; NIH centralizes peer review

Bio Pharma Dive

Elsewhere, AskBio advanced a gene therapy and Pfizer hired a scientist well versed in GLP-1 science. The Swiss pharma will base cardiometabolic drug research at the new Allston site.

article thumbnail

Merck and Synplogen to develop viral vector gene therapies

Pharmaceutical Technology

Merck and Synplogen have signed a non-binding Memorandum of Understanding (MoU) to expedite the development and manufacturing of viral vector-based gene therapy applications. The firms intend to merge their expertise to provide simplified viral vector gene therapy development, production and testing in Japan.

article thumbnail

Light-induced gene therapy disables cancer cells' mitochondria

Medical Xpress

In a new study, scientists combined strategies to deliver energy-disrupting gene therapy using nanoparticles manufactured to zero in only on cancer cells. Experiments showed the targeted therapy is effective at shrinking glioblastoma brain tumors and aggressive breast cancer tumors in mice.